High-dose daptomycin and fosfomycin treatment for endocarditis
Author Information
Author(s): Chen Liang-Yu, Huang Cheng-Hsiung, Kuo Shu-Chen, Hsiao Chen-Yuan, Lin Mei-Lin, Wang Fu-Der, Fung Chang-Phone
Primary Institution: Taipei Veterans General Hospital
Hypothesis
Combination therapy is more favorable than single-agent therapy for infections caused by daptomycin-nonsusceptible Staphylococcus aureus.
Conclusion
Combination therapy with high-dose daptomycin and fosfomycin is effective for treating endocarditis caused by daptomycin-nonsusceptible MRSA.
Supporting Evidence
- Combination therapy was used after the patient did not respond to initial treatments.
- The patient remained symptom-free during 12 months of follow-up after treatment.
- Surgical removal of the ICD device was performed as part of the treatment strategy.
Takeaway
Doctors used two strong medicines together to help a patient with a serious heart infection that didn't respond to regular treatment.
Methodology
The study involved a case report of a patient treated with high-dose daptomycin and fosfomycin, along with surgical intervention.
Limitations
The study is based on a single case report, limiting generalizability.
Participant Demographics
A 28-year-old woman with a history of implantable cardioverter-defibrillator device-related endocarditis.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website